Investor Relations

We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology.

NASDAQLPCN
YearTrailing 12-MonthsCalendar Year 2022Calendar Year 2021Calendar Year 2020Calendar Year 2019Calendar Year 2018Calendar Year 2017Calendar Year 2016Calendar Year 2015Calendar Year 2014Calendar Year 2013Calendar Year 2012Calendar Year 2011
ViewAll FilingsAnnual FilingsQuarterly FilingsCurrent FilingsRegistration StatementsSection 16Proxy & Information StatementsOther
FormDescriptionDateFormat
3Initial filing by director officer or owner of more than ten percent.Feb 14, 2012Open Initial filing by director officer or owner of more than ten percent. in HTML.Open Initial filing by director officer or owner of more than ten percent. in DOC file.Open Initial filing by director officer or owner of more than ten percent. in PDF file.Open Initial filing by director officer or owner of more than ten percent. in XLS file.